Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 9/20 | 0.70 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.63 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.63 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.63 |
| ▸ | SSTR4 | P31391 | 9/20 | 0.54 |
| ▸ | SSTR2 | P30874 | 8/20 | 0.54 |
| ▸ | SSTR3 | P32745 | 8/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 8/20 | 0.54 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15510980 | 1.00 | OXTR (0.70) | OXTRAVPR1BAVPR2AVPR1ASSTR4 | |
| SCHEMBL14060519 | 1.00 | OXTR (0.70) | OXTRAVPR1BAVPR2AVPR1ASSTR4 | |
| SCHEMBL324626 | 1.00 | OXTR (0.70) | OXTRAVPR1BAVPR2AVPR1ASSTR4 | |
| SCHEMBL15511844 | 0.88 | AVPR1B (0.68) | OXTRAVPR1BAVPR2AVPR1ASSTR4 | |
| SCHEMBL14008026 | 0.87 | OXTR (0.73) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL22333523 | 0.86 | OXTR (0.68) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL22333508 | 0.86 | OXTR (0.77) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL15512193 | 0.83 | OXTR (0.80) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL13827822 | 0.82 | OXTR (0.51) | OXTRAVPR1BAVPR2AVPR1ASSTR4 | |
| SCHEMBL15511961 | 0.82 | OXTR (0.88) | OXTRAVPR1BAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378668-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | SCRIPPS RESEARCH INST (US) | 2014-12-25 | — | — | US | disclosed |
| US-8765920-B2 | Tyrosine bioconjugation through aqueous Ene-like reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | THE SCRIPPS RESEARCH INSTITUTE | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378668-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | TYR, DNPEP, TH | OXTR 2299/4885AVPR1B 1709/4885AVPR2 2497/4885 |
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | TYR, DNPEP, TH | OXTR 2299/4885AVPR1B 1709/4885AVPR2 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.